MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M

MAXCYTE, INC.

Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).
Net loss $4.4M vs $3.0M; operating expenses $10.7M (+43%) on higher comp and professional costs.
Signed two new SPL agreements with Celularity and Sana Biotechnology for cell therapy platform.
Completed US IPO on Nasdaq raising $201.8M gross proceeds; cash $73.4M at June 30 pre-IPO.
Preliminary FY2021 revenue guidance of approximately $30M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.